Weill Cornell Medical College, 1300 York Ave, Room C 410-A, New York, NY 10021, USA.
J Clin Oncol. 2011 Sep 20;29(27):3659-68. doi: 10.1200/JCO.2011.35.1916. Epub 2011 Aug 22.
Prostate cancer is a common heterogeneous disease, and most patients diagnosed in the post prostate-specific antigen (PSA) era present with clinically localized disease, the majority of which do well regardless of treatment regimen undertaken. Overall, those with advanced prostate cancer at time of diagnosis do poorly after androgen withdrawal therapy. Understanding the biologic underpinning of prostate cancer is necessary to best determine the risk of disease progression and would be advantageous for the development of novel therapeutic approaches to impede or prevent disease. This review focuses on the recently identified common ETS and non-ETS gene rearrangements in prostate cancer. Although multiple molecular alterations have been detected in prostate cancer, a detailed understanding of gene fusion prostate cancer should help explain the clinical and biologic diversity, providing a rationale for a molecular subclassification of the disease.
前列腺癌是一种常见的异质性疾病，大多数在前列腺特异性抗原（PSA）时代后被诊断出患有局限性疾病的患者，无论采用何种治疗方案，大多数患者预后良好。总体而言，在雄激素剥夺治疗时被诊断为晚期前列腺癌的患者预后较差。了解前列腺癌的生物学基础对于最佳确定疾病进展的风险是必要的，并且有利于开发新的治疗方法来阻碍或预防疾病。这篇综述重点介绍了最近在前列腺癌中发现的常见 ETS 和非 ETS 基因重排。尽管在前列腺癌中已经检测到多种分子改变，但对基因融合前列腺癌的详细了解应该有助于解释临床和生物学多样性，为疾病的分子分类提供依据。
